• Product name

  • Description

    Rabbit polyclonal to PEG10/EDR
  • Host species

  • Tested applications

    Suitable for: WBmore details
  • Species reactivity

    Reacts with: Human
    Predicted to work with: Mouse
  • Immunogen

    Synthetic peptide corresponding to Mouse PEG10/EDR aa 350-450 conjugated to keyhole limpet haemocyanin.
    Database link: Q7TN75

  • Positive control

    • This antibody gave a positive signal in the following whole cell lysates: MDA MB 361; HepG2; PC3.
  • General notes

     This product was previously labelled as PEG10




Our Abpromise guarantee covers the use of ab151782 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
WB Use a concentration of 1 µg/ml. Detects a band of approximately 110 kDa (predicted molecular weight: 110 kDa).


  • Function

    Prevents apoptosis in hepatocellular carcinoma (HCC) cells through interaction with SIAH1, a mediator of apoptosis. May also have a role in cell growth promotion and hepatoma formation. Inhibits the TGF-beta signaling by interacting with the TGF-beta receptor ALK1. When overexpressed, induces the formation of cellular extension, such as filipodia in association with ALK1. Involved at the immediate early stage of adipocyte differentiation (By similarity). May bind to the 5'-GCCTGTCTTT-3' DNA sequence of the MB1 domain in the myelin basic protein (MBP) promoter.
  • Tissue specificity

    Expressed in the cytotrophoblast layer but not in the overlying syncytiotrophoblast of the placenta. Expressed in prostate and breast carcinomas but not in normal breast and prostate epithelial cells. Expressed in the HepG2 cell line (at protein level). Expressed in brain, liver, spleen, kidney, thymus, lung, ovary, testis, reactive lymph node, skeletal muscle, adipose tissue and placenta. Expressed in pancreatic and hepatocellular carcinomas (HCC).
  • Sequence similarities

    Contains 1 CCHC-type zinc finger.
  • Developmental stage

    Expressed in placenta during the first trimester of gestation (at protein level). In placenta, down-regulated at early hypoxic phase, and highly activated at 11-12 week of gestation.
  • Post-translational

    Isoform RF1/RF2 undergoes proteolytic cleavage.
  • Cellular localization

    Nucleus. Cytoplasm. Detected predominantly in the cytoplasm of breast and prostate carcinomas, in hepatocellular carcinoma (HCC) and B-cell chronic lymphocytic leukemia (B-CLL) cells and in the HepG2 cell line. Colocalized with ALK1.
  • Information by UniProt
  • Database links

  • Alternative names

    • AA407948 antibody
    • Edr antibody
    • Embryonal carcinoma differentiation regulated antibody
    • Embryonal carcinoma differentiation-regulated protein antibody
    • HB 1 antibody
    • HB1 antibody
    • KIAA1051 antibody
    • Mammalian retrotransposon-derived protein 2 antibody
    • Mar2 antibody
    • Mart2 antibody
    • MEF3 like 1 antibody
    • MEF3-like protein 1 antibody
    • MEF3L antibody
    • MEF3L1 antibody
    • MyEF 3 antibody
    • Myelin expression factor 3-like protein 1 antibody
    • Paternally expressed 10 antibody
    • Paternally expressed gene 10 ORF1 antibody
    • Paternally expressed gene 10 protein antibody
    • Peg10 antibody
    • PEG10 protein antibody
    • PEG10_HUMAN antibody
    • Putative uncharacterized protein PEG10 antibody
    • Retrotransposon gag domain containing 3 antibody
    • Retrotransposon gag domain-containing protein 3 antibody
    • Retrotransposon-derived gag-like polyprotein antibody
    • Retrotransposon-derived protein PEG10 antibody
    • RGAG3 antibody
    • Ty3/Gypsy-like protein antibody
    see all


  • All lanes : Anti-PEG10/EDR antibody (ab151782) at 1 µg/ml (Milk blocking - 1%)

    Lane 1 : MDA-MB-361 (Human breast adenocarcinoma cell line) Whole Cell Lysate Whole Cell Lysate
    Lane 2 : PC3 (Human prostate carcinoma cell line) Whole Cell Lysate Whole Cell Lysate
    Lane 3 : HepG2 (Human hepatocellular liver carcinoma cell line) Whole Cell Lysate
    Lane 4 : MDA-MB-361 (Human breast adenocarcinoma cell line) Whole Cell Lysate Whole Cell Lysate with Immunising peptide at 1 µg/ml
    Lane 5 : PC3 (Human prostate carcinoma cell line) Whole Cell Lysate Whole Cell Lysate with Immunising peptide at 1 µg/ml
    Lane 6 : HepG2 (Human hepatocellular liver carcinoma cell line) Whole Cell Lysate with Immunising peptide at 1 µg/ml

    Lysates/proteins at 25 µg per lane.

    All lanes : Goat Anti-Rabbit IgG H&L (HRP) (ab97051) at 1/10000 dilution

    Developed using the ECL technique.

    Performed under reducing conditions.

    Predicted band size: 110 kDa
    Observed band size: 110 kDa
    Additional bands at: 50 kDa (possible non-specific binding), 60 kDa (possible non-specific binding)

    Exposure time: 2 minutes

    This blot was produced using a 10% Bis-tris gel under the MOPS buffer system. The gel was run at 200V for 50 minutes before being transferred onto a Nitrocellulose membrane at 30V for 70 minutes. The membrane was then blocked for an hour using 1% Milk before being incubated with ab151782 overnight at 4°C. Antibody binding was detected using an anti-rabbit antibody conjugated to HRP, and visualised using ECL development solution.


ab151782 has not yet been referenced specifically in any publications.

Customer reviews and Q&As

There are currently no Customer reviews or Questions for ab151782.
Please use the links above to contact us or submit feedback about this product.

For licensing inquiries, please contact partnerships@abcam.com

Sign up